9 results
The main objective of this study is to investigate whether kidney transplant recipient suffering from a tacrolimus-induced tremor can benefit from switching from conventional tacrolimus to LCPT, a new extended release preparation of tacrolimus (…
The main objective of this pilot study is to investigate the feasibility of fluorescence imaging with the fluorescence agent bevacizumab-800CW to detect endometriosis tissue.
Primary objective:The objective is to evaluate if the LCPT dose can be reduced in comparison with tacrolimus-ER and still achieve similar tacrolimus levels in the therapeutic range in patients who are tacrolimus who need a relatively high dose of…
Primary objectives:The primary objectives are to evaluate the feasibility of oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE to shorten the qFME procedure and test whether…
Primary Objectives:To determine the optimal dose of the VEGF-targeting optical agent Bevacizumab-IRDye800CW for an adequate tumor-tobackgroundratio (TBR) during white-light (WL) / fluorescence-guided (FG) diagnostic laparoscopy (WL/FG-DLS) in…
The primary objective of this study is to investigate if the intra-patient variability in tacrolimus pharmacokinetics is reduced by switching patients from maintenance tacrolimus treatment with tacrolimus-Prograft to either Advagraf or to Envarsus.…
To determine the safety and feasibility of fluorescence imaging of the eye vascularization with the fluorescent tracer bevacizumab-800CW for identification of neovascular Age-related Macular Degeneration (AMD) with scanning laser angiography.
Primary:To evaluate the performance of FME with topical administration of Bevacizumab-800CW for detection of neoplasia in BE patients compared to HD-WLE to make an estimation of the diagnostic accuracy in terms of sensitivity and specificity in…
To investigate whether Envarsus® leads to a significant reduction in new onset diabetes, chronic kidney disease and new onset hypertension.